When clinicians’ attitudes toward general screening of the Ashkenazi Jewish population for the breast cancer (BRCA1/2) gene and LRRK2 mutations were compared,31 52% were in favor of BRCA screening, being an actionable finding, but 86% opposed LRRK2 screening, which currently has no specific treatment available. The gene discussed is LRRK2; the disease is breast cancer.